A comparison of the ventilatory, cardiovascular and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide in normal subjects.

Morice AH, Schofield P, Keal EE, Sever PS

British journal of clinical pharmacology1 Aug 1986Cited by 5 (Europe PMC)

PMID3756064PMCIDPMC1401100DOI10.1111/j.1365-2125.1986.tb05242.xPepBankPUB-03756064

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In six normal volunteers, VIP infusion did not significantly change the ventilatory response to carbon dioxide.
In plain wordsIn six healthy volunteers, VIP did not change the breathing response to carbon dioxide.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVentilatory response to carbon dioxide
Study
n = 6
Comparator
Placebo infusion
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol kg-1 min-1 · intravenous infusion · 30 minAs given in this study (human).
Source sentences
Summary
whereas salbutamol and VIP were without significant effect.
1 context sentence(design, population, supporting numbers)
Summary · context
Intravenous infusion of placebo for 30 min followed by either salbutamol 10 micrograms min-1, aminophylline 0.2 mg kg-1 min-1 or vasoactive intestinal peptide (VIP) 6 pmol kg-1 min-1 for 30 min was performed in a single blind fashion in six normal volunteers.
Report a problemFND-0375606401
02HumanNon-randomized trialEfficacy outcome
In six normal volunteers, VIP infusion caused a small tachycardia, a mean pulse increase of 2 beats per minute.
In plain wordsIn six healthy volunteers, VIP raised the pulse slightly, by about 2 beats per minute.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePulse rate
Study
n = 6
Comparator
Placebo infusion
Outcome group
Heart function · Cardiovascular
Studied dose
6 pmol kg-1 min-1 · intravenous infusion · 30 minAs given in this study (human).
Measurements
Pulse increase
2 beats min-1
VIP
Source sentences
Summary
All three drugs caused a tachycardia, mean increase in the pulse being 16, 8 and 2 beats min-1 for salbutamol, aminophylline and VIP respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Intravenous infusion of placebo for 30 min followed by either salbutamol 10 micrograms min-1, aminophylline 0.2 mg kg-1 min-1 or vasoactive intestinal peptide (VIP) 6 pmol kg-1 min-1 for 30 min was performed in a single blind fashion in six normal volunteers.
Report a problemFND-0375606402
03HumanNon-randomized trialSafety outcome
In six normal volunteers, VIP infusion caused haemoconcentration.
In plain wordsIn six healthy volunteers, VIP infusion made the blood more concentrated.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHaemoconcentration
Study
n = 6
Comparator
Placebo infusion
Outcome group
Electrolyte balance · Cardiovascular
Studied dose
6 pmol kg-1 min-1 · intravenous infusion · 30 minAs given in this study (human).
Source sentences
Summary
VIP caused haemoconcentration
1 context sentence(design, population, supporting numbers)
Summary · context
Intravenous infusion of placebo for 30 min followed by either salbutamol 10 micrograms min-1, aminophylline 0.2 mg kg-1 min-1 or vasoactive intestinal peptide (VIP) 6 pmol kg-1 min-1 for 30 min was performed in a single blind fashion in six normal volunteers.
Report a problemFND-0375606403

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In six normal volunteers, plasma catecholamines rose slightly during infusion of the study drugs, which included VIP; the abstract does not separate the drugs.
In plain wordsIn six healthy volunteers, plasma catecholamines rose slightly during drug infusion. The abstract does not say this was due to VIP alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma catecholamines
Study
n = 6
Comparator
Placebo infusion
Outcome group
Electrolyte balance · Cardiovascular
Source sentences
Summary
Plasma catecholamines increased slightly during drug infusion, although this effect is unlikely to be important.
1 context sentence(design, population, supporting numbers)
Summary · context
Intravenous infusion of placebo for 30 min followed by either salbutamol 10 micrograms min-1, aminophylline 0.2 mg kg-1 min-1 or vasoactive intestinal peptide (VIP) 6 pmol kg-1 min-1 for 30 min was performed in a single blind fashion in six normal volunteers.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0375606404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.